WebMay 28, 2024 · 8007 Background: BCMA-targeted immunotherapies offer considerable promise for relapsed/refractory MM. Teclistamab (JNJ-64007957) is a BCMA × CD3 bispecific IgG4 antibody that redirects CD3+ T cells to BCMA-expressing MM cells. We present updated results of patients (pts) treated at the recommended phase 2 dose … WebOct 25, 2024 · The pivotal Phase 2 MajesTEC-1 clinical trial included patients who had received a median of five prior lines of therapy (n=110). 1 An overall response rate (ORR) ... TECVAYLI™ is supplied as 30mg/3mL and 153mg/1.7mL single-dose vials. 1 “In the pivotal teclistamab study, we have continued to observe positive results in heavily pretreated ...
Did you know?
WebJun 8, 2024 · In the 2-part, open-label, first-in-human phase 1 MajesTEC-1 trial (NCT03145181), teclistamab was administered across 4 dosing cohorts, of which subcutaneous teclistamab 1500 µg/kg once weekly was identified as the recommended dose (RP2D), with step-up doses of 60 µg/kg and 300 µg/kg used to mitigate the risk for … WebJun 5, 2024 · CHICAGO, ILLINOIS, June 5, 2024 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from …
WebOct 19, 2024 · Teclistamab is a novel B-cell maturation antigen (BCMA) bispecific antibody that is being evaluated to treat participants with multiple myeloma, an incurable … WebStudy Design/Methods. MajesTEC-1 is a phase 1/2, first-in-human, open-label, multi-cohort, multicenter, dose escalation study evaluating TECVAYLI in patients with RRMM who …
WebJun 13, 2024 · In the phase I/II MajesTEC-1 trial presented at the 2024 ASCO Annual Meeting (Abstract 8007) and simultaneously published in The New England Journal of Medicine, Philippe Moreau, MD, and colleagues found that the bispecific antibody teclistamab produced responses in nearly two-thirds of patients with relapsed or … WebJun 2, 2024 · 8036 Background: Teclistamab is a B-cell maturation antigen × CD3 bispecific antibody currently being evaluated in MajesTEC-1 (NCT04557098), an open-label, single-arm, phase 1/2 trial in patients with RRMM who had received ≥3 prior lines of therapy (LOT) and were TCE to an immunomodulatory agent, a proteasome inhibitor, and an anti …
WebNov 23, 2024 · Introduction: Teclistamab (JNJ-64007957) is a T-cell redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to …
WebNov 10, 2024 · The tolerability profile of teclistamab after ≈ 9 months of follow up in MajesTEC-1 was consistent with earlier analyses, and no new safety signals were seen . Immunogenicity was assessed in 238 patients from MajesTEC-1; one patient (0.4%) developed low-titre neutralizing antibodies to teclistamab treatment . ev charging 2023WebOct 25, 2024 · Teclistamab-cqyv was evaluated in MajesTEC-1 (NCT03145181; NCT04557098), a single-arm, multi-cohort, open-label, multi-center study. first consumer financial quitman msWebDec 29, 2024 · MajesTEC-1 is a phase 1/2, first-in-human, open-label, dose-escalation study of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma. In the study, teclistamab achieved deep and durable responses with a manageable safety profile, according to updated findings recently presented during the American Society of ... ev charging 7kwWebFeb 7, 2024 · Prior data from the phase 1 MajesTEC-1 trial (NCT04557098) showed that teclistamab monotherapy, when given at the recommended phase 2 dose (RP2D), elicited an ORR of 65% and a VGPR or better rate ... first consumer cell phoneWebBackground: Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, demonstrated an overall response rate of 63.0% in 165 heavily pretreated patients with … ev charging 208vWebMar 29, 2024 · Incidence of CRS with teclistamab in MajesTEC-1 over time by grade. CRS was graded according to American Society for Transplantation and Cellular Therapy criteria. 6 If a patient had more than one event at a time point, the maximum grade is used. Repeat step-up before C1 is not displayed. One patient had a grade 1 CRS event after a repeat … ev charge softwareWebAug 21, 2024 · Background: There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the safety, tolerability, and … ev charging analyzer